Skip to main content

Table 1 Overview of basic characteristics of CVOTs completed 2016/17 and published in 2017

From: Report from the 3rd Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group

 

Study status

Drug

Drug class

Intervention

Primary outcome

N

Follow-up (years)

Start and end date

Clinicaltrials.gov ID

CANVAS program

Completed

Canagliflozin

SGLT-2 Inhibitor

Canagliflozin 100 mg vs. canagliflozin 300 mg vs. placebo

CV death, MI, or stroke

10,142

3.6

12.2009–02.2017

NCT01032629

EXSCEL

Completed

Exenatide

GLP-1 receptor agonist

Exenatide once-weekly vs. placebo

CV death, MI, or stroke

14,752

3.2

06.2010–04.2017

NCT01144338

DEVOTE

Completed

Insulin degludec

Basal insulins

Insulin degludec vs. Insulin glargine

CV death, MI, or stroke

7637

2.0

10.2013–10.2016

NCT01959529

ACE

Completed

Acarbose

α-glucosidase inhibitor

Acarbose vs. placebo

CV death, MI, or stroke, HHF,HUA

6522

5.0

02.2009–04.2017

NCT00829660

FOURIER

Completed

Evolocumab

PCSK9 inhibitor

Evolocumab vs. placebo

CV death, MI, stroke, UA or coronary revascularisation

27,564

2.2

01.2013–11.2016

NCT01764633